Investigation of the effect of mutations of rat albumin on the binding affinity to the alpha(4)beta(1) integrin antagonist, 4-[1-[3-chloro-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidine-2-yl]methoxybenzoic acid (D01-4582), using recombinant rat albumins.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Molecular Pharmaceutics

• Publication date

  2010-06-22

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1021/mp100061zPMID 20550182
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmaceutically important pre- and posttranslational modifications on human serum albumin.

  2009cited by this paper
• Marked Strain Differences in the Pharmacokinetics of an α4β1 Integrin Antagonist, 4-[1-[3-Chloro-4-[N-(2-methylphenyl)-ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidine-2-yl]-methoxybenzoic Acid (D01-4582), in Sprague-Dawley Rats Are Associated with Albumin Genetic Polymorphism

  2007cited by this paper
• Recombinant human serum albumin.

  2007cited by this paper
• Structural basis of the drug-binding specificity of human serum albumin.

  2005cited by this paper
• Molten-globule like partially folded states of human serum albumin induced by fluoro and alkyl alcohols at low pH.

  2004cited by this paper
• Functional Analysis of Recombinant Human Serum Albumin Domains for Pharmaceutical Applications

  2004cited by this paper
• Natalizumab for active Crohn's disease.

  2003cited by this paper
• Structural basis of albumin–thyroxine interactions and familial dysalbuminemic hyperthyroxinemia

  2003cited by this paper
• Inheritance and drug response.

  2003cited by this paper
• A controlled trial of natalizumab for relapsing multiple sclerosis.

  2003cited by this paper
• JAM2 interacts with alpha4beta1. Facilitation by JAM3.

  2002cited by this paper
• Crystal Structure Analysis of Warfarin Binding to Human Serum Albumin

  2001cited by this paper
• Expression of a Human Serum Albumin Fragment (Consisting of Subdomains IA, IB, and IIA) and a Study of Its Properties

  1999cited by this paper
• Species Differences of Serum Albumins: I. Drug Binding Sites

  1997cited by this paper
• Expression of a human serum albumin variant with high affinity for thyroxine.

  1995cited by this paper
• VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site.

  1990cited by this paper
• The characterization of two specific drug binding sites on human serum albumin.

  1975cited by this paper
• Determination of the secondary structures of proteins by circular dichroism and optical rotatory dispersion.

  1972cited by this paper

• Identification of trans-4-[1-[[7-fluoro-2-(1-methyl-3-indolyl)-6-benzoxazolyl]acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid as a potent, orally active VLA-4 antagonist.

  2012cites this paper